Which has better glucose control, Apart or Lipitor (Atorvastatin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Apart (Insulin Aspart) has better glucose control compared to Lipitor (Atorvastatin) is not a relevant comparison, as Lipitor is a statin and not an insulin or glucose control medication. However, considering the provided evidence, it's clear that the question is likely intended to compare the glucose control effects of different insulins, not statins like Atorvastatin. Among the insulins discussed in the evidence, such as Insulin Aspart, the most recent and highest quality study 1 compares Fiasp (an ultrarapid-acting insulin) to Insulin Aspart in hospitalized patients with type 2 diabetes, showing that Fiasp provides noninferior postprandial glucose control with no increase in hypoglycemia rates. For optimal glucose control with Insulin Aspart or similar rapid-acting insulins:

  • Inject immediately before meals
  • Start with an appropriate dose based on the patient's total daily insulin dose and meal composition
  • Adjust dose based on pre-meal and post-meal glucose readings It's essential to note that Atorvastatin (Lipitor) is used to lower cholesterol and does not directly affect glucose control. The management of diabetes involves medications that directly influence glucose levels, such as insulins and oral hypoglycemic agents. The choice of insulin should be based on the individual patient's needs, including the type of diabetes, lifestyle, and ability to monitor and adjust insulin doses. Close monitoring and dose adjustments are crucial when initiating or switching between insulins to achieve optimal glucose control and minimize the risk of hypoglycemia.

References

Research

Comparing Postprandial Glycemic Control Using Fiasp vs Insulin Aspart in Hospitalized Patients With Type 2 Diabetes.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.